Outcome
We developed a reliable, transferable multiplex TaqMan Absolute Q dPCR assay for lentiviral titration using proviral DNA + RNase P. This workflow delivers endpoint absolute quantification of integrated lentiviral genomes, reducing calibration burden and minimizing susceptibility to run-to-run variation.
By enabling accurate determination of infectious titer, MOI optimization, and vector copy number (VCN), the assay provides critical process and product insights for lentiviral vector manufacturing and gene-modified cell therapy development. These metrics support:
- Improved control of gene transfer efficiency
- Better-informed dose selection and MOI setting during transduction
- Stronger characterization for quality attributes linked to safety and performance
Overall, this case study supports digital PCR (dPCR) as a powerful tool for lentiviral infectious titer and VCN determination, helping advance cell and gene therapy programs targeting diseases such as cancer, HIV, cardiovascular disorders, neurodegenerative diseases, and asthma through more onsistent, data-driven development decisions.